Received Sep 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | UNK | — |
Inappropriate vaccination schedule (Late third dose); Inappropriate vaccination schedule (Late second dose); This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 60-year-old patient who received HAB (Twinrix) for prophylaxis. Co-suspect products included HAB (Twinrix) for prophylaxis. Previously administered products included Twinrix (received 1st dose of vaccine on 7th November 2024). On an unknown date, the patient received the 3rd dose of Twinrix. On 09-MAR-2025, the patient received the 2nd dose of Twinrix. On 09-MAR-2025, not applicable after receiving Twinrix and an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Inappropriate vaccination schedule (Late second dose)). On an unknown date, the patient experienced incomplete course of vaccination (Verbatim: Inappropriate vaccination schedule (Late third dose)). The outcome of the incomplete course of vaccination and drug dose administration interval too long were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 28-AUG-2025 The pharmacist called to ask about a sixty-year-old patient's vaccination schedule (revaccination or schedule restart) for the Twinrix vaccine. The pharmacist reactively stated, he/she was going to administer the third dose of Twinrix today (date of reporting).